Get the Stockscreener App
40.53
0.57%
0.23
After Hours:
40.85
0.32
+0.79%
Crispr Therapeutics Ag Stock (CRSP) Forecast
The Crispr Therapeutics Ag (CRSP) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $71.65, representing a +76.78% increase from the current price of $40.53. The highest analyst price target is $77.95, and the lowest is $65.35.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month CRSP Price Target
Average 92.73
(+128.80% Upside)
Is Crispr Therapeutics Ag (CRSP) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 44.09 | Neutral |
| STOCH(9,6) | 35.18 | Neutral |
| STOCHRSI(14) | 90.07 | Sell |
| MACD(12,26) | -1.6152 | Buy |
| ADX(14) | 17.56 | Neutral |
| William %R | -48.32 | Neutral |
| CCI(14) | 24.62 | Neutral |
Buy: 1
Sell: 1
Neutral: 5
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
40.34
Buy
|
40.18
Buy
|
| MA20 |
40.38
Buy
|
41.26
Sell
|
| MA50 |
45.65
Sell
|
44.04
Sell
|
| MA100 |
46.43
Sell
|
46.71
Sell
|
| MA200 |
51.13
Sell
|
50.34
Sell
|
Buy: 3
Sell: 7
Neutral: 0
Summary: Sell
According to our latest analysis, CRSP could be considered a Moderate Sell, with 17 technical analysis indicators signaling 4 Buy signals, 8 signaling Sell signals and 5 Neutral signals. This might not be a good time to consider opening new positions on CRSP, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 44.09 indicates that CRSP is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 35.18 indicates that CRSP is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 90.07 indicates that CRSP is oversold. This suggests that CRSP price is at or near the highest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 17.56 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 24.62 indicates that CRSP is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term CRSP price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Crispr Therapeutics Ag financial reports and earnings history, Crispr Therapeutics Ag (CRSP) stock could reach $72.11 by 2030, $105.70 by 2040 and $149.98 by 2050. See the projected annual prices until 2050 of the Crispr Therapeutics Ag stock below:
- Crispr Therapeutics Ag (CRSP) is expected to reach an average price of $104.57 in 2035, with a high prediction of $110.79 and a low estimate of $72.64. This indicates an $158.01% rise from the last recorded price of $40.53.
- Crispr Therapeutics Ag (CRSP) stock is projected to chart a bullish course in 2040, with an average price target of $99.32, representing an $145.06% surge from its current level. The forecast ranges from a conservative $93.35 to a sky-high $105.70.
- Our analysts predict Crispr Therapeutics Ag (CRSP) to jump 212.99% by 2045, soaring from $126.18 to an average price of $126.85, potentially reaching $140.20. While $126.18 is the low estimate, the potential upside is significant.
- Crispr Therapeutics Ag (CRSP) stock is expected to climb by 2050, reaching an average of $146.93, a $262.53% jump from its current level. However, a wide range of estimates exists, with high and low targets of $149.98 and $131.32, respectively, highlighting the market's uncertainty.
Crispr Therapeutics Ag Stock (CRSP) Year by Year Forecast
Crispr Therapeutics Ag Stock (CRSP) Price Forecast for 2025
Crispr Therapeutics Ag Stock (CRSP) is expected to reach an average price of $86.42 in 2025, with a high prediction of $126.48 and a low estimate of $46.36. This indicates an +113.23% rise from the last recorded price of $40.53.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| February, 2025 | $65.93 | $65.35 | $77.95 | +62.67% |
| March, 2025 | $65.81 | $61.02 | $75.10 | +62.37% |
| April, 2025 | $55.37 | $46.36 | $68.64 | +36.62% |
| May, 2025 | $67.70 | $52.21 | $70.22 | +67.04% |
| June, 2025 | $75.30 | $61.04 | $79.16 | +85.79% |
| July, 2025 | $83.07 | $72.29 | $85.24 | +104.95% |
| August, 2025 | $103.82 | $82.31 | $112.17 | +156.14% |
| September, 2025 | $104.21 | $97.93 | $111.38 | +157.13% |
| October, 2025 | $96.50 | $91.19 | $119.55 | +138.09% |
| November, 2025 | $98.19 | $93.00 | $103.40 | +142.26% |
| December, 2025 | $106.43 | $93.86 | $126.48 | +162.61% |
Crispr Therapeutics Ag Stock (CRSP) Price Forecast for 2026
The predicted value for Crispr Therapeutics Ag (CRSP) in 2026 is set at an average of $167.00. Estimates vary from a peak of $234.99 to a trough of $99.01, indicating an +312.04% surge from the present price of $40.53.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $136.22 | $99.01 | $139.10 | +236.11% |
| February, 2026 | $163.34 | $134.05 | $178.27 | +303.02% |
| March, 2026 | $214.67 | $161.35 | $234.99 | +429.66% |
| April, 2026 | $163.85 | $157.02 | $222.99 | +304.26% |
| May, 2026 | $144.54 | $114.90 | $161.90 | +256.62% |
| June, 2026 | $130.73 | $121.46 | $150.19 | +222.54% |
| July, 2026 | $121.70 | $110.17 | $152.62 | +200.28% |
| August, 2026 | $142.12 | $119.77 | $145.11 | +250.66% |
| September, 2026 | $159.53 | $134.71 | $184.93 | +293.60% |
| October, 2026 | $151.99 | $128.58 | $159.94 | +275.00% |
| November, 2026 | $140.27 | $130.89 | $157.91 | +246.08% |
| December, 2026 | $127.32 | $125.02 | $144.83 | +214.14% |
Crispr Therapeutics Ag Stock (CRSP) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Crispr Therapeutics Ag (CRSP) is $93.12, with a high forecast of $127.80 and a low forecast of $58.45. This indicates an +129.77% increase from the last price of $40.53.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $111.07 | $107.77 | $127.80 | +174.04% |
| February, 2027 | $97.95 | $97.43 | $114.06 | +141.67% |
| March, 2027 | $98.31 | $82.72 | $98.77 | +142.57% |
| April, 2027 | $83.41 | $80.40 | $99.19 | +105.81% |
| May, 2027 | $77.59 | $71.02 | $84.51 | +91.45% |
| June, 2027 | $68.97 | $66.29 | $82.22 | +70.17% |
| July, 2027 | $78.61 | $69.49 | $86.75 | +93.95% |
| August, 2027 | $71.58 | $70.68 | $86.27 | +76.61% |
| September, 2027 | $74.31 | $58.45 | $74.53 | +83.35% |
| October, 2027 | $86.03 | $69.39 | $91.44 | +112.27% |
| November, 2027 | $92.79 | $72.39 | $95.36 | +128.95% |
| December, 2027 | $94.83 | $88.52 | $103.07 | +133.97% |
Crispr Therapeutics Ag Stock (CRSP) Price Forecast for 2028
In 2028, Crispr Therapeutics Ag (CRSP) is projected to reach an average price of $76.12, with a high projection of $96.78 and a low estimate of $55.45. This indicates an +87.80% rise from the last price of $40.53.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $79.97 | $78.99 | $96.78 | +97.30% |
| February, 2028 | $81.64 | $77.33 | $91.43 | +101.42% |
| March, 2028 | $68.70 | $64.84 | $82.61 | +69.51% |
| April, 2028 | $71.41 | $64.89 | $80.63 | +76.19% |
| May, 2028 | $60.59 | $60.08 | $72.04 | +49.48% |
| June, 2028 | $66.16 | $55.45 | $70.73 | +63.25% |
| July, 2028 | $66.39 | $65.70 | $75.10 | +63.82% |
| August, 2028 | $59.91 | $58.70 | $70.14 | +47.81% |
| September, 2028 | $62.15 | $58.72 | $64.05 | +53.34% |
| October, 2028 | $72.60 | $60.16 | $74.70 | +79.12% |
| November, 2028 | $81.88 | $70.85 | $88.85 | +102.03% |
| December, 2028 | $73.08 | $71.94 | $85.16 | +80.32% |
Crispr Therapeutics Ag Stock (CRSP) Price Forecast for 2029
The 2029 price forecast for Crispr Therapeutics Ag Stock (CRSP) is $81.70 on average, with a high prediction of $108.63 and a low estimate of $54.78. This represents an +101.58% increase from the previous price of $40.53.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $74.35 | $70.16 | $76.64 | +83.44% |
| February, 2029 | $66.77 | $63.11 | $73.98 | +64.74% |
| March, 2029 | $67.72 | $64.70 | $69.06 | +67.08% |
| April, 2029 | $61.51 | $57.90 | $67.73 | +51.76% |
| May, 2029 | $70.43 | $54.78 | $76.08 | +73.78% |
| June, 2029 | $85.98 | $65.84 | $93.49 | +112.14% |
| July, 2029 | $79.99 | $72.57 | $94.32 | +97.36% |
| August, 2029 | $80.42 | $75.71 | $85.89 | +98.41% |
| September, 2029 | $101.52 | $79.56 | $108.63 | +150.47% |
| October, 2029 | $89.21 | $87.96 | $108.16 | +120.11% |
| November, 2029 | $72.71 | $71.93 | $90.71 | +79.40% |
| December, 2029 | $67.14 | $65.02 | $76.35 | +65.66% |
Crispr Therapeutics Ag Stock (CRSP) Price Forecast for 2030
Crispr Therapeutics Ag Stock (CRSP) is expected to reach an average price of $81.03 in 2030, with a high forecast of $101.65 and a low forecast of $60.42. This signifies an +99.94% surge from the last price of $40.53.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $69.94 | $61.83 | $72.11 | +72.56% |
| February, 2030 | $75.87 | $69.70 | $77.08 | +87.19% |
| March, 2030 | $77.33 | $74.93 | $80.95 | +90.79% |
| April, 2030 | $73.10 | $70.77 | $77.55 | +80.35% |
| May, 2030 | $68.11 | $68.09 | $77.49 | +68.05% |
| June, 2030 | $67.47 | $62.84 | $68.96 | +66.46% |
| July, 2030 | $89.62 | $68.12 | $101.59 | +121.11% |
| August, 2030 | $95.68 | $91.12 | $101.65 | +136.07% |
| September, 2030 | $87.62 | $85.01 | $97.73 | +116.20% |
| October, 2030 | $83.97 | $78.44 | $89.08 | +107.19% |
| November, 2030 | $64.98 | $62.88 | $87.46 | +60.33% |
| December, 2030 | $67.81 | $60.42 | $73.63 | +67.31% |
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):